206 related articles for article (PubMed ID: 23943412)
1. Depression and impulsivity as pathways to violence: implications for antiaggressive treatment.
Krakowski MI; Czobor P
Schizophr Bull; 2014 Jul; 40(4):886-94. PubMed ID: 23943412
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
[TBL] [Abstract][Full Text] [Related]
3. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
Krakowski MI; Czobor P; Nolan KA
J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
[TBL] [Abstract][Full Text] [Related]
4. Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.
Krakowski MI; Czobor P
J Clin Psychiatry; 2012 Jan; 73(1):74-80. PubMed ID: 22152404
[TBL] [Abstract][Full Text] [Related]
5. The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol.
Krakowski M; Tural U; Czobor P
Am J Psychiatry; 2021 Mar; 178(3):266-274. PubMed ID: 33472389
[TBL] [Abstract][Full Text] [Related]
6. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Volavka J; Czobor P; Nolan K; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Lieberman JA
J Clin Psychopharmacol; 2004 Apr; 24(2):225-8. PubMed ID: 15206671
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
Bitter I; Czobor P; Dossenbach M; Volavka J
Eur Psychiatry; 2005 Aug; 20(5-6):403-8. PubMed ID: 16084068
[TBL] [Abstract][Full Text] [Related]
8. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
[TBL] [Abstract][Full Text] [Related]
9. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
Krakowski M; Czobor P; Citrome L
Schizophr Res; 2009 May; 110(1-3):95-102. PubMed ID: 19269139
[TBL] [Abstract][Full Text] [Related]
10. Reducing Restraint With Clozapine in Involuntarily Admitted Patients With Schizophrenia.
Ifteni P; Szalontay AS; Teodorescu A
Am J Ther; 2017; 24(2):e222-e226. PubMed ID: 27984264
[TBL] [Abstract][Full Text] [Related]
11. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA
Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
[TBL] [Abstract][Full Text] [Related]
12. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
13. Violence and schizophrenia: clozapine as a specific antiaggressive agent.
Buckley P; Bartell J; Donenwirth K; Lee S; Torigoe F; Schulz SC
Bull Am Acad Psychiatry Law; 1995; 23(4):607-11. PubMed ID: 8639988
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.
Krakowski M; Czobor P
Schizophr Res; 2011 Aug; 130(1-3):27-33. PubMed ID: 21549568
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital.
Hotham JE; Simpson PJ; Brooman-White RS; Basu A; Ross CC; Humphreys SA; Larkin F; Gupta N; Das M
CNS Spectr; 2014 Oct; 19(5):403-10. PubMed ID: 24284256
[TBL] [Abstract][Full Text] [Related]
17. The effects of clozapine on aggression and substance abuse in schizophrenic patients.
Volavka J
J Clin Psychiatry; 1999; 60 Suppl 12():43-6. PubMed ID: 10372611
[TBL] [Abstract][Full Text] [Related]
18. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
Volavka J; Czobor P; Cooper TB; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Lieberman JA
J Clin Psychiatry; 2004 Jan; 65(1):57-61. PubMed ID: 14744169
[TBL] [Abstract][Full Text] [Related]
19. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
20. The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study.
Spivak B; Shabash E; Sheitman B; Weizman A; Mester R
J Clin Psychiatry; 2003 Jul; 64(7):755-60. PubMed ID: 12934974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
